Pain/anesthesia companies
15 listed pain/anesthesia companies, largest first, with lead program and the next catalyst each has disclosed.
| Company | Ticker | Lead program | Indication | Next catalyst |
|---|---|---|---|---|
| Mesoblast Ltd | MESO | rexlemestrocel-L | chronic low back pain associated with degenerative disc disease | — |
| Pacira BioSciences, Inc. | PCRX | EXPAREL (bupivacaine liposome injectable suspension) | postsurgical local and regional analgesia | H2 2026 — LG Chem to file for marketing authorization in Thailand |
| Not specified in extract | Not specified in extract | onzotrigine | moderate to severe acute pain, including postoperative pain | H2 2026 — Initiate placebo-controlled Phase 3 trial in bunionectomy and open-label Phase 3 safety trial |
| Collegium Pharmaceutical, Inc | COLL | Commercial portfolio (Jornay PM, Azstarys, Belbuca, Xtampza ER, Nucynta, Symproic) | ADHD and moderate to severe pain | — |
| Tonix Pharmaceuticals Holding Corp. | TNXP | TONMYA (cyclobenzaprine sublingual, TNX-102 SL) | fibromyalgia | H1 2027 — OASIS ASD topline |
| Heron Therapeutics, Inc. | HRTX | ZYNRELEF (bupivacaine and meloxicam) | Postsurgical analgesia for up to 72 hours after soft tissue and orthopedic surgery | — |
| Dogwood Therapeutics, Inc. | DWTX | Halneuron (tetrodotoxin, Nav1.7 modulator) | Chemotherapy-induced neuropathic pain (CINP) | H2 2026 — Start of Phase 1b patient dosing in CIPN |
| Mira Pharmaceuticals, Inc. | MIRA | Ketamir-2 | chemotherapy-induced peripheral neuropathy (CIPN) | Q1 2027 — Initiation of Phase 2a trial in CIPN |
| Scilex Holding Co | SCLX | ZTlido (lidocaine topical system) 1.8% | neuropathic pain associated with postherpetic neuralgia | — |
| Ensysce Biosciences, Inc. | ENSC | PF614 | Severe/chronic pain (abuse-resistant TAAP oxycodone prodrug) | — |
| Tenon Medical, Inc. | TNON | The Catamaran SI Joint Fusion System | sacroiliac joint disorders / lower back pain | — |
| Creative Medical Technology Holdings, Inc. | CELZ | Olastrocel (CELZ-201, ADAPT trial) | chronic lower back pain due to degenerative disc disease | — |
| Aclarion, Inc. | ACON | Nociscan (NOCISCAN suite: NOCICALC / NOCIGRAM) | Chronic discogenic low back pain (surgical decision support) | — |
| Autonomix Medical, Inc. | AMIX | Autonomix transvascular sensing and RF ablation catheter system | Pain associated with pancreatic cancer | H2 2026 — Commencement of planned US-based IDE clinical trials (subject to new financing) |
| Apimeds Pharmaceuticals US, Inc. | APUS | APITOX | Pain associated with osteoarthritis (and other indications) | 2027 — Contemplated spin-off of the BioBusiness / distribution of 51% of Lokahi equity (approx. twelve months from 2026-04-24) |
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.